ASCVD drug trial terminated due to insufficient efficacy
15 October, 2015Eli Lilly and Company (Lilly) will terminate its phase 3 trial of the investigational medicine evacetrapib due to insufficient efficacy.
Myelin researcher scores AbbVie Student Poster Award
13 October, 2015The 2015 AbbVie Student Poster Awards recognised the important research being carried out by Australian graduate students in areas such as pharmaceutical sciences, disease research, biology and nutritional science.
Cancer and blood researchers elected as AAHMS fellows
09 October, 2015Three researchers from the Walter and Eliza Hall Institute have been elected as fellows of the Australian Academy of Health and Medical Sciences in recognition of their contributions to Australian medical research.
Australia partners with the US on brain research
01 October, 2015The NHMRC and the US National Institutes of Health have opened a joint funding round as part of the BRAIN Initiative — part of a presidential focus aimed at revolutionising our understanding of the human brain.
Fusion cancer treatment to be developed by Clarity
11 September, 2015Clarity Pharmaceuticals has signed an exclusive licensing agreement with CRO Fusion Antibodies to further develop a Cathepsin S-specific antibody for the treatment of cancer.
Funding a cure for type 1 diabetes
11 September, 2015Researchers based at the Westmead Millennium Institute for Medical Research and Westmead Hospital have been awarded $3.3 million to extend their research into a clinical cure for type 1 diabetes.
Call for breast cancer assay to be reimbursed
08 September, 2015Medical experts have called for the Oncotype DX Breast Cancer Assay, developed by Genomic Health, to be considered for reimbursement in Australia.
11 NHMRC grants for international research collaborations
04 September, 2015The NHMRC has announced 11 grants to support international collaborative research on health issues such as heart attacks, dementia, stroke and leukaemia.
Patents and positive clinical data from Prescient
01 September, 2015Prescient Therapeutics has announced the acquisition of two new US patents to protect its cancer drug PTX-200, which last week provided the company with encouraging early clinical data in an ongoing study.
Leslie Chong appointed Imugene COO
28 August, 2015Imugene has appointed Leslie Chong as its new chief operating officer as of mid-September — a move which saw the company's share price rise by 25% on Thursday.
2015–18 NHMRC committee members announced
26 August, 2015Experts in health ethics, policy, patient care and innovation are among those who have been appointed to the National Health and Medical Research Council's five committees.
Specialised Therapeutics to distribute European oncology drug
21 August, 2015Specialised Therapeutics Australia has formed an exclusive licence and commercialisation agreement with PharmaMar to market and distribute the oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.
Prima receives milestone payment for anticancer antibody program
17 August, 2015Prima BioMed will receive a clinical milestone payment from Novartis relating to the latter's IMP701 LAG-3 antibody, which is being trialled for the treatment of cancer.
Medical Research Future Fund passes Senate
13 August, 2015Legislation for the Medical Research Future Fund (MRFF) has successfully passed through the Senate with bipartisan support, with assurance from the government that the fund will meet the needs of the medical research community.
Cancer screening pioneer joins Clinical Genomics
11 August, 2015Clinical Genomics has announced clinical diagnostics pioneer Howard Chandler as its inaugural Emeritus Scientist. Chandler is the inventor of the patient-friendly 'brush' form of faecal immunochemical test (FIT).
